In healthcare screening, different guideline organizations may offer varying recommendations, and cervical cancer screening is no exception. Cervical cancer is almost always caused by persistent infection with high-risk HPV strains. Routine screening has significantly reduced cervical cancer deaths, making regular check-ups crucial since early detection enables more effective treatment of precancerous conditions. Dr. Kathy MacLaughlin, a family physician at Mayo Clinic specializing in cervical cancer prevention, explains that Mayo Clinic follows the recommendations of the U.S. Preventive Services Task Force (USPSTF). These guidelines suggest screening for individuals aged 21 to 65, with options including a Pap test every three years, a combined Pap/HPV test starting at age 30 every five years, or a primary HPV test every five years.
Innovations in Screening Accessibility
Beginning February 5, Mayo Clinic’s Midwest locations will offer FDA-approved self-collected HPV testing to help reduce barriers to screening, with plans to expand this service to Arizona and Florida campuses. For women aged 21–65, the USPSTF recommends: cervical cytology (Pap test) every three years for those aged 21–29; and for ages 30–65, either cervical cytology every three years, high-risk HPV testing every five years, or co-testing every five years.
When to Stop Screening
Current guidelines suggest that most individuals may discontinue screening after age 65 if they have a history of negative/normal results, particularly over the past decade. However, Dr. MacLaughlin notes exceptions: those with a history of precancerous lesions (CIN-2 or CIN-3), prior LEEP procedures, immunosuppression, cervical cancer history, or in-utero DES exposure should continue screening. To cease screening at 65, patients must have no these risk factors and a documented history of either three negative Pap tests or two negative HPV tests over ten years.
Risk Factors and Prevention Strategies
Persistent high-risk HPV infection is the primary cause of most cervical cancers. Any sexually active individual with a cervix is at risk, particularly if unvaccinated against HPV. Other risk factors include smoking, lack of screening, and having multiple sexual partners. Prevention involves three key steps: HPV vaccination (most effective when administered during adolescence but recommended for ages 9–26 and considered for ages 27–45 through shared decision-making), adherence to screening intervals, and appropriate management of abnormal results.
Interpreting Self-Collected HPV Test Results
Approximately 85–90% of self-collected tests will return negative for HPV, with repeat testing recommended in three years (though intervals may extend to five years pending guideline updates). For positive results, further evaluation is needed. Detection of HPV 16 or 18—strains responsible for 70% of cervical cancers—requires referral for colposcopy, an outpatient procedure examining the cervix under magnification, possibly with biopsies. If other high-risk HPV types are detected, patients must return for a Pap test to guide next steps, as self-collected samples cannot be used for cytology. This scenario is expected in about 10% of cases. The USPSTF is updating its recommendations to include self-collection as an option for ages 30–65.
Related:
